Latest news with #NuclearMedicine
CTV News
08-07-2025
- Health
- CTV News
‘It gives us hope': Quebec expands access to life-extending prostate cancer treatment
A life-altering treatment for prostate cancer with fewer side effects is now more accessible in Quebec. A Quebec man who has spent years fighting for access to a promising prostate cancer treatment says he was overcome with emotion when the province finally approved it last week. Jean Krashevski was first diagnosed with aggressive prostate cancer in 2015. After surgery and 33 rounds of radiation, he hoped the disease was behind him. But within a year and a half, it returned — this time spreading to other parts of his body, including his brain. 'I should be dead by now,' he said. 'But we moved quickly, and we fought hard. This new treatment gives us something we haven't had in a long time: hope.' Pluvicto, the drug for this treatment, is a radiopharmaceutical therapy that delivers targeted radiation directly to prostate cancer cells. It's designed for patients with metastatic castration-resistant prostate cancer who have already undergone hormone therapy and chemotherapy. On July 2, the Quebec government added it to the province's list of publicly covered medications. For Krashevski, who launched a petition a year ago demanding the province fund Pluvicto, it was a long-awaited breakthrough. 'I couldn't believe it when we got the news,' he said. 'I was with my family and we all cried because this treatment is a game-changer — not just for me, but for so many men waiting for this.' Dr. Frédéric Arsenault, president of the Association of Nuclear Medicine Specialists of Quebec, calls the decision 'a milestone.' 'There was a clear gap in treatment options for patients with advanced prostate cancer,' he said. 'Pluvicto fills that gap — it not only prolongs life, but it does so with better quality and fewer to no side effects.' The therapy works by binding to a protein found on the surface of prostate cancer cells called PSMA (prostate-specific membrane antigen). A radioactive atom then delivers targeted radiation directly to the tumour. Because it attacks only the cancer cells and not healthy tissue, Dr. Arsenault explained that the treatment avoids some of the harsh side effects of traditional therapies, including erectile dysfunction, severe fatigue, and damage to surrounding organs. In clinical trials, Pluvicto led to a 50 per cent drop in PSA levels, the key blood marker used to monitor prostate cancer, and significantly delayed disease progression. Until now, patients in Quebec had to pay $27,000 per dose out of pocket, with a full course of six doses totalling over $160,000. Dr. Arsenault said some were able to access it under RAMQ's 'exceptional medications' program, but only on a case-by-case basis with added red tape. Years of waiting and fighting Like many medical experts and prostate cancer patients, Krashevski had been following Pluvicto's development closely. His wife Céline, a biologist, has helped him navigate research, protocols, and treatment options since his diagnosis. Together, they advocated for the drug's approval in Quebec, speaking to doctors, politicians, and the media. 'It was an uphill battle,' he said. 'Some officials were sympathetic but told me their hands were tied, others were dismissive.' Krashevski has undergone multiple rounds of hormone therapy and other treatments that have taken a toll on his body and mind. He continues to stay active — practicing martial arts in a more meditative way — but said the effects of cancer are far-reaching. 'Your sex life changes entirely — you also lose your strength and your muscle mass,' he said. 'Psychologically, it's tough too because you're always just gaining time — one more day, one more treatment — waiting and hoping that something new will come.' He has just undergone a new round of imaging tests and is waiting for the green light to begin Pluvicto. 'I'd love to start tomorrow but there's a protocol,' he said. 'Raising awareness remains key' Krashevski said he wants other men to speak up about prostate cancer — and get screened early, especially if there's a family history. 'It's a simple blood test, and, if you catch it early, the treatment is much easier,' he said. 'Once it metastasizes, it's a whole different ballgame.' He also urged patients to be proactive in their own care — to ask questions, seek second opinions, and bring a trusted person to medical appointments to take notes and advocate. 'We have great doctors here in Quebec, but time is of the essence when you're diagnosed,' he said. 'Don't wait.' Another encouraging aspect of Pluvicto is its potential beyond treating prostate cancer. Dr. Arsenault said the drug is being studied for a range of other cancers, including breast, gastric, liver, and pancreatic cancer. That research is already underway, including in Quebec at McGill's Jewish General Hospital. 'We think that in the next 10 years, there could be 10 other types of cancer or other diseases that will benefit from this kind of treatment,' he said. For now, Krashevski is focused on the next steps in his care. And for the first time in a long time, he says, he's optimistic. 'For a while, I had lost hope, but this news gives me the chance to keep fighting,' he said. 'And, after all these years, I'm still hoping for a chance at full remission.'
Yahoo
03-07-2025
- Health
- Yahoo
Business and Investment Opportunities in Nuclear Medicine 2025-2030: North America Leads, Asia-Pacific Races
Nuclear Medicine Market Dublin, July 03, 2025 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics, Therapeutics), Application (Cardiology, Neurology, Oncology), End-use (Hospitals, Diagnostic Centers), and Region with Growth Forecasts, 2025-2030" has been added to Nuclear Medicine Market was valued at USD 17.77 billion in 2024, and is projected to reach USD 34.51 billion by 2030, rising at a CAGR of 10.16%. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer. Nuclear Medicine Market Report Highlights By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications. The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer. By application, the oncology segment dominated the market in 2024. North America dominated the market with a share of 42.87% in 2024, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability. The Asia-Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period. According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency's (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes Report Attribute Details No. of Pages 170 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $17.77 Billion Forecasted Market Value (USD) by 2030 $34.51 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Key Topics CoveredChapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Product and Application Outlook2.2.2. End Use Outlook2.2.3. Regional Outlook2.3. Competitive Insights Chapter 3. Nuclear Medicine Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent Market Outlook3.1.2. Related/Ancillary Market Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.1.1. Rising Incidence of Cancer and Cardiovascular Diseases3.2.1.2. Increasing Application of Radiopharmaceuticals/Nuclear Medicine3.2.1.3. Growing Demand for Accurate Diagnostic Methods3.2.2. Market Restraint Analysis3.2.2.1. High Cost of Treatment3.2.2.2. Stringent Regulations Pertaining to Production, Storage, & Usage3.3. Nuclear Medicine Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL Analysis3.3.3. Pipeline Analysis Chapter 4. Nuclear Medicine Market: Product Estimates & Trend Analysis4.1. Global Nuclear Medicine Market: Product Dashboard4.2. Global Nuclear Medicine Market: Product Movement Analysis4.3. Global Nuclear Medicine Market by Product, Revenue4.4. Diagnostics4.5. Therapeutics Chapter 5. Nuclear Medicine Market: Application Estimates & Trend Analysis5.1. Global Nuclear Medicine Market: Application Dashboard5.2. Global Nuclear Medicine Market: Application Movement Analysis5.3. Global Nuclear Medicine Market Estimates and Forecasts, by Application, Revenue (USD Million)5.4. Cardiology5.5. Neurology5.6. Oncology5.7. Thyroid5.8. Lymphoma5.9. Bone Metastasis5.10. Endocrine Tumor5.11. Pulmonary Scans5.12. Urology5.13. Others Chapter 6. Nuclear Medicine Market: End Use Estimates & Trend Analysis6.1. Global Nuclear Medicine Market: End Use Dashboard6.2. Global Nuclear Medicine Market: End Use Movement Analysis6.3. Global Nuclear Medicine Market Estimates and Forecasts, by End Use, Revenue (USD Million)6.4. Hospitals6.5. Diagnostic Centers6.6. Others Chapter 7. Nuclear Medicine Market: Regional Estimates & Trend Analysis by Product, Application, and End Use7.1. Regional Dashboard7.2. Market Size, & Forecasts Trend Analysis, 2018 to 20307.3. North America7.4. Europe7.5. Asia-Pacific7.6. Latin America7.7. MEA Chapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, by Key Market Participants8.2. Company/Competition Categorization8.3. Vendor Landscape8.3.1. List of Key Distributors and Channel Partners8.3.2. Key Customers8.3.3. Key Company Market Share Analysis, 20248.3.4. GE Healthcare8.3.5. Jubilant Life Sciences Ltd.8.3.6. Nordion (Canada), Inc.8.3.7. Bracco Imaging S.p.A.8.3.8. The Institute for Radioelements (IRE)8.3.9. NTP Radioisotopes SOC Ltd.8.3.10. The Australian Nuclear Science and Technology Organization8.3.11. Eczacibasi-Monrol8.3.12. Lantheus Medical Imaging, Inc.8.3.13. Eckert & Ziegler8.3.14. Mallinckrodt8.3.15. Cardinal Health For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Nuclear Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-06-2025
- Business
- Yahoo
Integrated Theranostics Solutions and Bridge Oncology Launch Turnkey Theranostics Program to Help Fast-Track Radioligand Therapy Adoption
Strategic partnership brings Nuclear Medicine and Oncology together to advance the future of Theranostics PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today announced a strategic partnership that brings together two leading consulting service providers to offer the market's only full-service, end-to-end solution for building and scaling theranostics programs. This exclusive collaboration equips private oncology clinics, independent urology practices, academic health systems, and regional networks, looking to enter theranostics, with the operational, clinical, and financial tools needed in one of medicine's fastest growing fields. Healthcare providers used to face months of delays trying to assemble expertise across multiple facets like regulatory compliance protocols, imaging infrastructure, revenue cycle operations and staffing models for theranostics. Many gave up before seeing patient results. "Today, organizations can launch a complete theranostics program with a single partner — from site readiness and clinical workflows to billing optimization and multi-site scaling — without juggling multiple vendors or long timelines," explained Adam Brown, founder of ITS. This comprehensive service offering brings together strong subject matter expertise in Nuclear Medicine, Theranostics, and Radiation Oncology to provide full program execution to help organizations effectively meet the demand to improve patient access to new diagnostic and therapeutic options. These services integrate eight key pillars, which include: Assessment and Strategic Planning Patient Care Coordination Regulatory Compliance Imaging and Equipment Integration Revenue Cycle Management Staffing Solutions Site Design and Readiness Training and Education "With the global Theranostics market projected to grow from $4.3 billion in 2024 to $12.7 billion by 2029,1- healthcare organizations are under increasing pressure to enter the space with confidence and speed," explained Jordan Johnson, CEO of Bridge Oncology. "The need for turnkey, low-risk program development for theranostics treatments has never been greater." "By joining forces, we can deliver a high-quality theranostics program in a financially sustainable way, streamlining reimbursement and cost recovery," Brown continued. "Although these types of programs can be complex, when they are executed well, they can support multi-site expansion, boost the institutional reputation, and support physician recruitment." While every engagement is tailored to a unique, organization-based strategy, the combined service line is intended to bridge the gap between innovation and implementation to accelerate program adoption and revenue generation, providing flexible solutions. "This marks the first time nuclear medicine and radiation oncology have come together to help make theranostics a practical reality," said Dr. Arpit Chhabra, a practicing radiation oncologist and partner in Bridge Oncology. "By integrating diagnostic imaging with targeted therapeutic intervention, we can achieve more accurate tumor characterization and deliver personalized treatment plans that elevate the standard of patient care. Ready to remove the roadblocks in your Theranostics journey? Book a call through our website and let's make it happen. 1Global Theranostics Market to Triple, Reaching $12.7 Billion by 2029." BCC Research, 26 Sept. 2024 For further information, please contact: Adam BrownIntegrated Theranostics SolutionsTime Zone: CST – Central time Tel: 770-715-9892Email: info@ About Integrated Theranostics Solutions Integrated Theranostics Solutions (ITS) is a consulting and management firm dedicated to advancing the field of theranostics. ITS bridges the gap between innovation and implementation, helping healthcare providers, researchers, and industry leaders navigate the complexities of theranostics with strategic insights and tailored solutions. From operational guidance to program development and everything in between, ITS supports the growth and integration of theranostics in clinical and research settings. About Bridge Oncology Bridge Oncology is a healthcare consulting and services company that supports all aspects of oncology care for clinical, financial, and operational excellence. With more than 20 years' experience supporting integrated cancer care practices and community oncology programs, Bridge Oncology is a trusted partner for organizations seeking to improve clinical workflow, create greater operational efficiency, and maximize financial performance. View original content to download multimedia: SOURCE Bridge Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mail
06-06-2025
- Health
- Daily Mail
Doctor reveals 'haunting' sound people make when they have less than 24 hours to live
When a person is nearing the end of their life, a particularly eerie symptom could indicate death is just hours away, a doctor has revealed. Dr Paulien Moyaert, a Nuclear Medicine Resident and Researcher, from Belgium, explained that a distinctive phenomenon, hauntingly dubbed 'the death rattle', can manifest in someone's final moments. It occurs when a person can no longer effectively clear secretions from their throat, leading to the accumulation of fluids such as saliva and mucus. As the body weakens - and swallowing or coughing becomes less effective - a disturbingly wet clattering can hence be heard during breathing. Taking to her YouTube channel, where she often explains complex medical topics, Dr Moyaert, spoke about its causes, prognosis and treatment. 'A person usually lives for 23 hours after the death rattle begins,' she recounted. 'With each breath the person may make a moaning, snoring or rattling sound. 'This occurs because as consciousness decreases, patients lose their ability to swallow. Air moves these pooled secretions resulting in noising breathing. 'Some people say that the death rattle is the lungs' attempt to breathe through a layer of saliva.' However, the expert revealed that while the sound may be distressing to those nearby, it does not cause discomfort to the individual experiencing it. 'We often give drugs to try dry up the airways and soften the death rattle, but when we do it, it's not for the dying person but for their family,' she added. 'Repositioning the patient so that they're turned to their side with their head slightly elevated may also help.' Commenters rushed to remark on the 'haunting' symptom - admitting it left them feeling 'uncomfortable'. However, many also found it helpful to better process their experiences with losing loved ones. 'My friend is dying in Florida and her daughter is keeping me updated,' one remarked. 'She referenced a "death rattle" in one of her updates and I wasn't sure what that was. Thank you for explaining it.' Many rushed to the comments to thank the doctor for clearly explaining the phenomenon - albeit admitting the sound is 'haunting' Another added: 'Thank you for this, my mum made these sounds for a couple days before she died (she was not awake at this point but eyes open, rattle breathe etc) 'Although this video was pretty triggering I'm really glad to be able to find closure about the sound. 'It was really haunting and still makes me uncomfortable to think about (it sounded like she was choking and trying to clear her throat) anyway lol sorry for the rant, thank you for this.' 'THIS, is the sound that indicates that your loved one is about to take their next steps of their journey!' one penned. 'No more pain, or suffering, but TRUE PEACE!!! This may sound HORRIBLE, but just know your loved one isn't suffering!' A fourth added: 'This was invaluable information as my mother passed away this morning. She started making this noise yesterday, and it was so distressing to hear. I'm thankful to know she was not in pain, and the meds we gave her were for our benefit. Thanks again.' The death rattle occurs in about 40 percent of people during the dying phase, according to studies. The noise can be reduced using medications to dry the mouth or by turning a patient onto their side to allow fluids building up to spill out. Units generally avoid using suction because this can cause the body to ramp up its mucus production, making the problem worse. In the days to hours before death, doctors say patients may experience a sudden and brief surge in energy before suddenly having much less. As well as the rattle, their breathing may also become more erratic, their pulse weakened and their hands and feet may become cold, purple and blotchy. And in the final minutes, the eyes and mouth may remain open - as breaths could become more gasping.
Times of Oman
11-05-2025
- Health
- Times of Oman
Royal Hospital achieves highest quality standards in nuclear medicine endorsed by IAEA
Musca t: The Royal Hospital, represented by the Department of Nuclear Medicine, has completed the QUANUM programme (Quality Assurance Audit in Nuclear Medicine Practices) that was conducted by the International Atomic Energy Agency (IAEA). The programme, held from 4 to 8 May 2025, set grounds for the first nuclear medicine centre in the Sultanate of Oman that undergoes this type of international assessment. The field assessment of the centre showed an outstanding score of 92.5 percent, exceeding the global average of 73.9 percent and going beyond the usual range of 56.6% to 87.9%.
